We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Impax Laboratories has sued the Federal Trade Commission for improperly deciding that it’s 2010 settlement with Endo Pharmaceuticals over Opana ER (oxycodone extended release) was anticompetitive. Read More
The U.S. Sixth Circuit Court of Appeals threw out Ohio Attorney General Dave Yost’s attempt to stop the Oct. 21 opioid bellwether trial of two Ohio counties against drugmakers and distributors. Read More
The company was accused of paying kickbacks to patients by covering patient copayments regardless of financial need and paying telemedicine physicians to write prescriptions without a legitimate prescriber-patient relationship. Read More
The FDA issued a complete response letter to Tanvex BioPharma for its proposed biosimilar for Amgen’s Neupogen (filgrastim) for the creation of white blood cells following chemotherapy. Read More
Johnson & Johnson said it will contest a Philadelphia jury’s decision to award $8 billion to a man who claimed its drug Risperdal (risperidone) caused him to grow breasts. Read More
The FDA’s Office of Prescription Drug Promotion (OPDP) sent a warning letter to Galt Pharmaceuticals for sending an email to doctors about its insomnia pill Doral (quazepam) that left out the fact that the drug is a benzodiazepine, a class-four controlled substance. Read More